AptarGroup Inc. Common Stock (ATR)

FairStock Score: 49/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is asking $119.21 as of October 13, 2026 for a steady dispensing and drug-delivery business. Aptar earns decent returns on equity—13.46% per FairStock—and carries modest debt with D/E 0.53. Its Piotroski F-Score is a perfect 9/9 and Altman Z 3.04, so financial distress seems remote. Free cash flow is $323.9M, a 4.3% FCF yield, which supports a 1.54% dividend. But the price is not a bargain by Graham's arithmetic: the Graham Number is $71.62, leaving a negative margin of safety of 66.45%. The P/E of 21.52 and P/B of 2.88 already price in steady improvement. Growth has been uneven. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.0B, net income $87.6M, and diluted EPS $1.36, versus fiscal Q2 2025 net income $111.7M and diluted EPS $1.67. For FY2025, revenue was $3.8B, net income $392.8M, and diluted EPS $5.89, up from FY2024 net income $374.5M and diluted EPS $5.53. FairStock classifies it a STALWART: profit grew 12.9% a year over five years, revenue 5.2%. ROCE of 6.14% is only moderate, so the moat is real but not fortress-like. The shares sit below the 52-week high of $146.91, but at 10.5 times EV/EBITDA and a 49/100 FairStock score, I see a fair-to-full price for a good, not exceptional, compounder.

In plain English: AptarGroup makes pumps, closures, and drug-delivery systems for medicine, beauty, and consumer products. The business is steadily profitable and financially strong, but recent profit slipped and the stock looks expensive compared with its earnings and asset value. The dividend is modest, and while the shares are below their 52-week high, they do not look clearly cheap on the numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer